We exist because Duchenne muscular dystrophy should not

As a company founded by those touched by the disease, we aim to be a center of excellence for advancing the science of Duchenne muscular dystrophy (Duchenne). Our deep commitment to the patient community is at the heart of what we do. For every approach we take, we put the needs of patients and their families at the forefront.

It is our responsibility to ensure that the patient voice and perspective is at the core of the company’s DNA, woven into every step of our research, development and clinical programs. We value our relationships with the patient community and continually engage in discussions to help ensure our activities in all areas address the unmet needs of patients, their caregivers and families with a sense of urgency.

Our dedication to discover and develop novel therapeutic approaches for Duchenne, and ultimately a cure, guides us every day. We are motivated by the prospect that there will be an end to Duchenne and remain committed to doing our part to advance the science to combat this devastating disease.

Please feel free to contact us with questions and ideas: community@solidbio.com.

Annie Ganot
Head of Patient Advocacy